Anixa BiosciencesANIX +12.14%27 Return-on-Tangible-Equity is -68.11% as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,200 Biotechnology companies, Anixa Biosciences ranks worse than 61.75% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Anixa Biosciences's annualized net income for the quarter that ended in Apr. 2026 was $-10.06 Mil. Anixa Biosciences's average shareholder tangible equity for the quarter that ended in Apr. 2026 was $14.78 Mil. Therefore, Anixa Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Apr. 2026 was -68.11%.
The historical rank and industry rank for Anixa Biosciences's Return-on-Tangible-Equity or its related term are showing as below:
ANIX'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -637.36 Med: -102.66 Max: -36.76
Current: -64.84
During the past 13 years, Anixa Biosciences's highest Return-on-Tangible-Equity was -36.76%. The lowest was -637.36%. And the median was -102.66%.
ANIX's Return-on-Tangible-Equity is ranked worse than 61.75% of 1200
companies
in the Biotechnology industry
Industry Median: -42.435
vs ANIX: -64.84
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Anixa Biosciences Return-on-Tangible-Equity Related Terms
Anixa Biosciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Anixa Biosciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANIX vs BMEA, PMN, ATRA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Anixa Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anixa Biosciences Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Apr. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -68.11% mean?
Anixa Biosciences (ANIX) has a Return-on-Tangible-Equity of -68.11% as of Apr. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Anixa Biosciences and its competitors. According to the industry distribution chart, Anixa Biosciences ranks #741 out of 1200 companies in the Biotechnology industry, placing it in the top 61.7%.
Is Anixa Biosciences' Return-on-Tangible-Equity too high?
Anixa Biosciences' current Return-on-Tangible-Equity is -68.11%. Based on the distribution chart, Anixa Biosciences ranks #741 out of 1200 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Return-on-Tangible-Equity compare to BMEA and PMN?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #741 out of 1200 companies for Return-on-Tangible-Equity. This places Anixa Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current Return-on-Tangible-Equity is -68.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Return-on-Tangible-Equity of -68.11%. The current Return-on-Tangible-Equity is -68.11%. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Return-on-Tangible-Equity is -68.11% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score
Get the complete analysis for ANIX
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIX has been successfully added to your 
